It is intended to ameliorate arteriosclerosis or arteriosclerotic disease through a pharmacological mechanism that reduces the size of the arteriosclerotic lesion. The agent of the present invention comprises a complex comprising an antibody binding to folate receptor beta (FRbeta) and a cytotoxin or a cytotoxic agent conjugated with the antibody, or the antibody as an active ingredient.